South Carolina Medicaid and tirzepatide
Zepbound for weight loss: not confirmed. No state document read names Zepbound. The November 2025 minutes speak of GLP-1 medications for obesity without naming it, and the October 2026 PDL and GLP-1 criteria omit it, but absence is not a no. scdhhs.gov and its provider manual returned 403. Mounjaro for weight loss: no. Requires a documented type 2 diabetes diagnosis, with metformin and A1c requirements. Also needs a trial or failure of preferred products.; for type 2 diabetes South Carolina Medicaid must cover it. Read from South Carolina Department of Health and Human Services documents Nov 6, 2026.
Mounjaro · Prime Therapeutics for SCDHHS
“Exenatide, Liraglutide, Mounjaro (tirzepatide), Soliqua (lixisenatide/insulin glargine), Victoza (liraglutide), Xultophy (liraglutide, insulin degludec)”
read Nov 6, 2026
Mounjaro · Prime Therapeutics for SCDHHS
“The patient meets the criteria listed above.”
read Nov 6, 2026
In 2025 South Carolina Medicaid paid for 9,970 tirzepatide prescriptions (Mounjaro, Zepbound), 15% of its GLP-1 prescriptions and 33rd of the 50 states and DC. It reimbursed $9.5 million before rebates, $948 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 8,529 | $8.0 million | $942 |
| Zepbound | 1,441 | $1.4 million | $983 |
Tirzepatide in the states around South Carolina
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| South Carolina | 16 | $69/moWellmedr | 9,970 | Medicaid Zepbound: Not confirmed |
| Georgia | 16 | $69/moWellmedr | 8,964 | Medicaid Zepbound: Not covered (KFF) |
| North Carolina | 17 | $69/moWellmedr | 84,091 | Medicaid Zepbound: Yes |



